ASX Announcement 18 November 2026 Chairman’s Address to 2026 Annual General Meeting Sydney, Australia – 18 November 2026: OncoSil Medical Limited (ASX: OSL) (“OncoSil Medical” or “the Company”), a medical device company focused on localised treatments for patients with unresectable...
AGM Chairman's Address and CEO & MD Presentation
Filed with ASX · · 16 pages · English
Summary by 6ix AI
OncoSil Medical Ltd has released the Chairman's address and CEO presentation for its Annual General Meeting, detailing significant achievements and transitions for the company during the past financial year. The address highlights the approval of the OncoSil device for treating pancreatic cancer and distal cholangiocarcinoma, marking a pivotal moment for commercial expansion in major markets. The company reported substantial growth in unit sales and revenue, alongside important regulatory milestones that position it for future success. Looking ahead, OncoSil aims to launch its product in the United States and Australia while expanding its clinical applications and commercial adoption across Europe.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Release
In the deck
Earlier from OncoSil Medical
- OncoSil to Present at Bell Potter Healthcare Conference 2026
- Regulatory Application Filed for Australian Manufacturing
- Quarterly Activities/Appendix 4C Cash Flow Report
- Annual Report (Typeset)
- Peer-Reviewed Study Reports 100% Disease Control
Later from OncoSil Medical
All OncoSil Medical news releasesFollow OncoSil Medical into a list and get an email when it puts out news.
Follow OncoSil Medical